🇺🇸 FDA
Patent

US 11104719

Recombinant clusterin and use thereof in the treatment and prevention of disease

granted A61KA61K38/00A61K9/0019

Quick answer

US patent 11104719 (Recombinant clusterin and use thereof in the treatment and prevention of disease) held by The Board of Regents of the University of Texas System expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/00, A61K9/0019, A61K9/19, A61P